Mortality after emergency presentation: evidence from a cohort of 929 378 Medicare beneficiaries with common cancers diagnosed 2008-2017

Clicks: 1
ID: 320895
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #101 of 329 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 329 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Emergency presentation (EP) for cancer diagnosis is associated with higher mortality, but prior research has largely focused on select cancer types or non-U.S. populations. We estimated EP prevalence and associated mortality across 16 cancers in a national Medicare cohort. METHODS: Using SEER-Medicare data, we identified patients with 16 high-burden cancers diagnosed 2008-2017. EP was defined by an ED claim within 30 days before the index cancer claim and subtyped as inpatient EP (emergency hospitalization) or outpatient EP (following ED discharge). We estimated survival probabilities and mortality risk ratios (RRs) adjusted for demographics, tumor characteristics, comorbidity, frailty, and healthcare utilization. RESULTS: Among 929,378 patients, 28% were EPs (22% inpatient, 6% outpatient). EP prevalence ranged from <10% (breast, prostate) to > 40% (liver, lung, stomach, colon, ovarian, pancreatic cancers). One-year survival was 81% for non-EPs, 60% for outpatient EPs, and 36% for inpatient EPs. Compared with non-EPs, inpatient EPs had nearly 4-fold higher 30-day adjusted mortality (RR = 3.88, 95% CI: 3.81-3.96), ranging from 2.1 (pancreas) to 6.3 (lymphoma). Among 90-day survivors, inpatient EPs had 51% higher one-year mortality (RR = 1.51, 1.49-1.52), ranging from 1.1 (pancreas) to 2.1 (lymphoma). Outpatient EPs showed intermediate risk (one-year mortality RR = 1.28, 1.26-1.30). CONCLUSION: EP is common and predicts persistently elevated mortality in older U.S. adults after comprehensive covariate adjustment. Associations were strongest for cancer types underrepresented in prior research, including hematologic malignancies, breast, prostate, and bladder cancers. Routine EP monitoring could improve risk stratification at diagnosis and guide efforts to reduce avoidable emergency presentations.
Reference Key
openalex_W7168276441 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Caroline A Thompson, Yuelin He, Sarah E Soppe, Xueer Zhang, Megan A Mullins, Matthew E Barclay, Nicholas Pettit, Allison W Kurian, Ellis C Dillon, Sandi Pruitt, Georgios Lyratzopoulos
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag236
URL
https://doi.org/10.1093/jnci/djag236
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.